These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Depot medroxyprogesterone acetate contraceptive injections and skeletal health. Renner RM; Edelman AB; Kaunitz AM Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597 [No Abstract] [Full Text] [Related]
26. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda. Grabowski MK; Gray RH; Makumbi F; Kagaayi J; Redd AD; Kigozi G; Reynolds SJ; Nalugoda F; Lutalo T; Wawer MJ; Serwadda D; Quinn TC; Tobian AAR Lancet Glob Health; 2015 Aug; 3(8):e478-e486. PubMed ID: 26094162 [TBL] [Abstract][Full Text] [Related]
27. Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness. Whiteman MK; Jeng G; Samarina A; Akatova N; Martirosyan M; Kissin DM; Curtis KM; Marchbanks PA; Hillis SD; Mandel MG; Jamieson DJ Contraception; 2016 Jan; 93(1):17-24. PubMed ID: 26197261 [TBL] [Abstract][Full Text] [Related]
28. Retinal venous occlusion associated with depot medroxyprogesterone acetate. Deen BF; Shuler RK; Fekrat S Br J Ophthalmol; 2007 Sep; 91(9):1254. PubMed ID: 17709596 [No Abstract] [Full Text] [Related]
29. Accounting for anovulation and vaginal thinning during depot medroxyprogesterone acetate use. Atrio J J Infect Dis; 2015 Mar; 211(5):850. PubMed ID: 25217405 [No Abstract] [Full Text] [Related]
30. Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices. Birse KD; Romas LM; Guthrie BL; Nilsson P; Bosire R; Kiarie J; Farquhar C; Broliden K; Burgener AD J Infect Dis; 2017 Feb; 215(4):590-598. PubMed ID: 28011908 [TBL] [Abstract][Full Text] [Related]
31. A Fixed Drug Eruption to Medroxyprogesterone Acetate Injectable Suspension. Patel K; Cervantes JA; Keeling B; Adamson AS Cutis; 2022 Mar; 109(3):E12-E14. PubMed ID: 35659137 [No Abstract] [Full Text] [Related]
32. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk. Schooling CM Lancet HIV; 2015 Sep; 2(9):e366. PubMed ID: 26423548 [No Abstract] [Full Text] [Related]
33. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk. Seidman D; Averbach S; Smith-McCune K; Darney P Lancet HIV; 2015 Sep; 2(9):e365-6. PubMed ID: 26423545 [No Abstract] [Full Text] [Related]
34. Pigmented purpuric dermatosis as a delayed reaction to medroxyprogesterone acetate. Rose RF; Bishop R; Goulden V J Eur Acad Dermatol Venereol; 2008 Sep; 22(9):1150-1. PubMed ID: 18422540 [No Abstract] [Full Text] [Related]
35. Is medroxyprogesterone safe in women with long QT syndrome? Skinner JR; Vandenberg JI Heart Rhythm; 2012 Jul; 9(7):1148-9. PubMed ID: 22401936 [No Abstract] [Full Text] [Related]
36. Gynecology case challenge: vaginal bleeding in a woman taking an injectable contraceptive. Hill DA Medscape Womens Health; 1998 Jan; 3(1):4. PubMed ID: 9732093 [No Abstract] [Full Text] [Related]
37. Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss. Wooltorton E CMAJ; 2005 Mar; 172(6):746. PubMed ID: 15743913 [No Abstract] [Full Text] [Related]
38. 'Black box' warning added to contraceptive injection. FDA Consum; 2005; 39(2):3. PubMed ID: 16124078 [No Abstract] [Full Text] [Related]
39. New aspects of injectable contraception. Phillips OP Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618 [TBL] [Abstract][Full Text] [Related]
40. Thrombocytopenic purpura with depot medroxyprogesterone acetate and subsequent use of contraceptive implant: making decisions in the absence of evidence. Holman R; Stephen G J Fam Plann Reprod Health Care; 2005 Oct; 31(4):333-4. PubMed ID: 16274569 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]